Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Karolina WojtowiczMaciej Zabel

Abstract

Multidrug resistance proteins are one of the most important factors that cause chemotherapy resistance, which in turn reduces therapeutic efficacy and survival for cancer patients. Tunicamycin is one of the most well-known inhibitors of N-glycosylation and is considered a powerful adjunct that can increase the effectiveness of many drugs. Tunicamycin blocks the first step of P-gp (glycoprotein P) and BCRP (breast cancer resistance protein) N-glycosylation, which is a very important modification for the activity and cellular localisation of these proteins. The effects of tunicamycin on ovarian and colorectal cancer cells were examined in multiple cell lines. The primary ovarian cancer cell line W1 and the established ovarian cancer cell line A2780 were compared against their drug-resistant derivatives W1TR/W1PR (TR: topotecan resistant; PR: paclitaxel resistant) and A2780T1 (topotecan resistant), respectively. We also compared the colorectal cancer cell line LoVo against its doxorubicin-resistant derivative LoVo/Dx. Cell viability was determined by the MTT assay. The glycopeptides were subjected to deglycosylation using the endoglycosidase PNGase F. A2780T1, LoVo/Dx and W1PR cells were treated with the protein degradation inhibi...Continue Reading

References

Jun 1, 1988·Journal of the National Cancer Institute·L M GreenbergerS B Horwitz
Oct 1, 1995·Current Opinion in Structural Biology·G S Jacob
Feb 6, 1999·International Journal of Cancer. Journal International Du Cancer·I NodaH Saito
Jun 22, 1999·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·J W DennisC E Warren
Dec 3, 1999·Science·L EllgaardA Helenius
Sep 14, 2002·The Journal of Biological Chemistry·Ling SongRichard S Jope
Dec 10, 2002·Current Protein & Peptide Science·A MolinariG Arancia
Aug 19, 2005·The Journal of Biological Chemistry·Ulla HenriksenUlrik Gether
Oct 5, 2006·Mini Reviews in Medicinal Chemistry·Sandrine Gerber-Lemaire, Lucienne Juillerat-Jeanneret
May 12, 2009·Glycobiology·Ajit Varki
Oct 12, 2010·Cancer Chemotherapy and Pharmacology·Julio Cesar Madureira de Freitas JuniorJosé Andrés Morgado-Díaz
Mar 14, 2013·BioMed Research International·Radosław JanuchowskiMaciej Zabel
Apr 23, 2013·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Witold SzaflarskiMaciej Zabel
May 15, 2013·Asian Journal of Andrology·Xiaojing QianC Yan Cheng
Dec 20, 2013·Lancet·Paolo Vineis, Christopher P Wild

❮ Previous
Next ❯

Citations

Jul 26, 2016·Frontiers in Oncology·Leonardo Marques da FonsecaMárcia Alves Marques Capella
Oct 30, 2016·Therapeutic Delivery·Serap YalçınUfuk Gündüz
Oct 12, 2018·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Guowei ZhangJianguo Gu
Apr 28, 2019·International Journal of Molecular Sciences·Monika ŚwierczewskaRadosław Januchowski
Sep 15, 2018·Oncology Letters·Rendy HoseaSeptelia Inawati Wanandi
Dec 26, 2018·International Journal of Molecular Sciences·Karolina SterzyńskaRadosław Januchowski
Jan 10, 2018·Biological & Pharmaceutical Bulletin·Kentaro YanoTakuo Ogihara
Oct 30, 2020·Frontiers in Oncology·Hongbo Zhang, Wei Han
Jul 18, 2020·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Nuray ErinThomas Efferth

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.